Click Therapeutics, Inc.’s Post

🔬Dr. David Systrom Discusses OMF’s LIFT Clinical Trial 🔬 Today Dr. David Systrom sits down to chat about OMF's first clinical trial, The Life Improvement Trial (LIFT). Watch the video interview 👉 https://ow.ly/PH9750Q5gSn. What is The LIFT? Conducted under the direction of David Systrom, MD, Director of our Harvard Collaboration and Jonas Bergquist, MD, PhD, OMF’s Chief Medical Officer and Director of the Uppsala University Collaboration, The LIFT is a randomized, double-blind placebo trial that will investigate two particular drugs: Pyridostigmine (commonly known as Mestinon) and low-dose naltrexone (LDN) separately and together as a combination. Dr. Systrom speaks more on trial setup, expected timelines of the trial, why this is an important first step, and more.

Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this FREE webinar Sara Riordan, MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment, discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register now ⤵ https://lnkd.in/gRg3gwC4

I might have said this before, but I’ll say it again… You don’t want to miss this webinar! Working directly with patients to determine their best treatment options including all acces mechanisms is the future. We all deserve the level of consideration and opportunity that will be detailed in this presentation. Make sure you don’t let this one slip through the cracks. #patientcentric #telehealth #geneticcounseling #healthtech

Dr Shoona Vincent, our Vice President of Clinical Science, recently gave a presentation at Clinical Trials Europe on the use of psychedelics in clinical trials. He discussed MAC’s previous experience with psychedelics and explained the existing infrastructure and support we have in place for our clinical trials. More specifically, he explored the operational challenges that come with working with psychedelics such as participant selection and the effective use of placebos. You can access a recording of the presentation here: https://lnkd.in/eyntN7hf     Find out more about our experience in psychedelics: https://lnkd.in/ek-HE6RF  #cro #clinicalresearch #psychedelics #psychedelicresearch

Check out this talk on the operational challenges and considerations in conducting clinical trials with psychedelics💡 - Set and Setting - Schedule 1 licences - Which model of psychological support? - Rating scales/Raters vs therapists - Participant selection - naive vs non-naive? - Blinding/placebo challenges MAC has now conducted 14 trials with psychedelic compounds to date - further information in the link below 👇 #psychedelicresearch #psilocybin #DMT #Ibogaine #LSD #MDMA #ketamine #clinicaltrials

Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this webinar Sara Riordan MS, CGC, Genome Medical;  Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register: https://lnkd.in/gRg3gwC4

Advances in therapeutic drug and device development have resulted in enormously favorable impacts on symptoms and outcomes for patients with heart failure. A network meta-analysis of clinical trials in heart failure over the past 40+ years reported that contemporary therapy with the foundational guideline-directed medical therapies was associated with an estimated 60% reduction in all-cause mortality (1), an astounding achievement.   Partnerships between academic thought leaders, sponsors and industry, regulators and the clinical trial infrastructure environment of CROs, along with innumerable site investigators and coordinators, have all enabled this progress.   CCS is proud to support clinical research to advance the science of therapeutic and drug development for patients with heart failure. #HFWeek2024 #HFSA https://lnkd.in/dumpmy8   1Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CSP, Voors AA. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10:73-84. PMID: 34895860.

With the presentation of MODULAR ATP and APPRAISE ATP clinical trial data, it’s an exciting day here at #HRS2024. Together, these data reinforce the promise of the groundbreaking mCRM System, and illustrate a clear path forward for physicians to offer therapies that prevent sudden cardiac death and deliver antitachycardia pacing (ATP) for the patients who benefit from it. The investigational mCRM System offers a potential upgrade pathway for patients currently implanted with the EMBLEM™ S-ICD System who develop a need for ATP or pacing, allowing physicians to tailor therapy to a patient’s individual needs. Congratulations to the team at Boston Scientific who made the study a success, principal investigators Reinoud Knops M.D. PhD and Claudio Schuger, and those who have supported these important studies! Congratulations also on the simultaneous publication of the MODULAR ATP results in the New England Journal of Medicine, where the results are now available: https://lnkd.in/eEE72t77 * Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.

Experts Emma Field and Erin Schaller explore the benefits of a clinical logistics monitor to expertly guide the cellular starting material and subsequent therapy through the clinical trial journey. » https://bit.ly/3TSJZgc #celltherapy #earlyclinicaldevelopment #clinicaltrials

Modular ATP & APPRAISE ATP data continues to show the importance of evidence-based medicine and BSC’s commitment to this space. We are excited about these results to help further advance CRM therapy. #BSCCardiology #HRS2024